Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

San Diego Convention Center

Jun 16, 2024 7:00 AM - Jun 20, 2024 3:00 PM

111 W Harbor Drive, , San Diego, CA 92101 , USA

DIA 2024 Global Annual Meeting

Join us at the premier life sciences conference, celebrating our 60th anniversary! Discover 180+ sessions on Cell and Gene Therapy, Decentralized Clinical Trials, AI, ICH, and more. Get ready to tackle challenges, improve skills, network, and drive change for healthcare at DIA2024.

Considerations for Identification of Drug-Induced Liver Injury

Session Chair(s)

James  Buchanan, PharmD

James Buchanan, PharmD

President

Covilance LLC, United States

Identification of drug-induced liver injury (DILI) is hindered by the lack of a structured, standardized approach to its identification and evaluation. This leads to inefficiencies for both sponsors and regulators. Guidance related to data submission for DILI evaluation can improve the efficiency of regulatory review, for example, by reducing the number of information requests sent by the FDA to industry sponsors. Ultimately, improved strategies for DILI data gathering and submission will also improve the accuracy of DILI risk assessment. This session will provide an in-depth discussion of the challenges for reviewing clinical data and suggest potential strategies to improve the DILI identification process. Topics that will be covered include (1) regulatory guidance on structured DILI data submission, (2) how interactive data visualizations tools can enhance the ability to detect potential cases of DILI and (3) the approach to populations with elevated transaminases at baseline and why the modified eDISH (mDISH) approach has important limitations.

Learning Objective : Describe the regulatory guidance for how to submit structured data pertaining to drug-induced liver injury (DILI) data; Discuss how to utilize interactive visualization tools to identify potential cases of DILI; Identify the challenges for detecting DILI when liver tests are abnormal at baseline.

Speaker(s)

Y. Veronica  Pei, MD, MEd, MPH

Regulatory Guidances for Submitting Structured DILI Data

Y. Veronica Pei, MD, MEd, MPH

FDA, United States

Acting Associate Director, Biomedical Informatics and Regulatory Review Science

James  Buchanan, PharmD

Use of Interactive Visualization Tools to Identify Potential Cases of DILI

James Buchanan, PharmD

Covilance LLC, United States

President

Paul  Hayashi, MD, MPH

Addressing the Challenges of DILI Detection in Clinical Trials with Abnormal Baseline Liver Tests

Paul Hayashi, MD, MPH

FDA, United States

Associate Director of DILI, Division of Hepatology and Nutrition, OND, CDER

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.